Introduction

Since 2008, Evaxion Biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using Artificial Intelligence, with the mission to solve some of the world’s most significant challenges to human health.

Using cutting-edge immunology, bioinformatics, and machine learning methods, Evaxion Biotech is discovering and developing 'best in class’ vaccines for infectious diseases and cancer at an unprecedented rate. We have constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, PIONEER and EDEN. Using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. EDEN enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while PIONEER has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them.

Introduction

Since 2008, Evaxion Biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using Artificial Intelligence, with the mission to solve some of the world’s most significant challenges to human health.

Using cutting-edge immunology, bioinformatics, and machine learning methods, Evaxion Biotech is discovering and developing 'best in class’ vaccines for infectious diseases and cancer at an unprecedented rate. We have constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, PIONEER and EDEN. Using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. EDEN enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while PIONEER has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them.

Our dedicated team of talented bioinformaticians and scientists are spearheading the field of immunoinformatics, working rigorously to bring novel, broadly protective vaccines and therapies to a largely unmet medical need within cancer and infectious diseases.
Our in silico antigen and neoepitope discovery platforms have been programmed to specially identify the most suitable targets for vaccines and antibodies, and is initiating clinical development in 2018.

Evaxion Biotech collaborates with leading vaccine companies and institutions on the development of highly efficacious immunotherapies.

Our Company.

Our Company.

From our office located centrally in Copenhagen, our talented bioinformaticians work hard to discover protective antigens and epitopes against bacteria and discover personalized, efficacious neoepitopes against cancer. Preclinical development is performed in our own labs as well as through collaboration with leading labs and medical schools in Copenhagen and Boston, USA.

Evaxion is building on a simple and scalable business model with manageable risk. Evaxion’s core capability is utilization of our Artificial Intelligence platforms to discover novel vaccines and antibodies.  We have a strong focus on early vaccine and antibody development and building alliances.

Evaxion has a strong track record of collaborating with leading human and veterinary vaccine companies. Evaxion is also collaborating with US academic and Governmental institutions and has gained support from Defense Advanced Research Project Agency (DARPA).

© Copyright 2018 EVAXION BIOTECH All rights reserved